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In the yeast Saccharomyces cerevisiae, the CDC25 gene product is supposed to interact with ras proteins and adenylate cyclase for progression 
through the cell division cycle. To identify the CDC25 gene product, we raised antibodies against wo hybrid proteins, encoded by in-frame fusions 
between the E. coli IacZ gene and two different parts of the CDC25 gene. By protein immuno-blotting, we were able to identify the CDC25 gene 
product as a 180 kDa polypeptide, which we named ~180 cDc2s. It was detected only when the CDC25 gene was overexpressed ina proteases-deficient 
yeast strain. Subcellular fractionation experiments showed that p180cDczJ, as well as ras proteins, is attached to the membrane, even after treatments 
which release peripheral membrane proteins. 
Cell cycle; Signal transduction; RAS; CAMP pathway 
1. INTRODUCTION 
During the cell division cycle of Saccharomyces 
cerevisiae, CAMP plays a major role for completion of 
the START step of the Gl phase [ 11. Adenylate cyclase, 
the product of the CDC35 gene [2-41, is activated by 
two ras proteins encoded by two distinct genes, RASZ 
and RAS2 [5,6]. Like their mammalian homologs, 
yeast ras proteins bind guanine nucleotides and display 
a weak GTPase activity [7]. Only the GTP-bound form 
is able to activate adenylate cyclase [8]. Another key 
element in the yeast CAMP production pathway is the 
CDC25 gene product [9- 111. After a shift to the non- 
permissive temperature, the phenotype of cdc25 ther- 
mosensitive mutants is very similar to that of cdc35 
mutants: Gl arrest and rapid drop of the intracellular 
CAMP level [9]. Genetic and biochemical studies sug- 
gest that the CDC25 gene product could interact with 
ras proteins, increasing the GDP dissociation rate, 
leading to a higher proportion of the active (ras-GTP) 
complex [ 10-141. Ras proteins and adenylate cyclase 
are well characterized. By contrast, very little is known 
about the CDC25 gene product. DNA sequence shows 
an open reading frame capable of encoding a 1589 
amino acid polypeptide [9,11,15]. The CDC25 gene is 
transcribed into a 5200 bases mRNA [9,16]. To identify 
the CDC25 gene product, we constructed in-frame fu- 
sions between the E. coli 1acZ gene and various por- 
tions of the CDC25 gene and we used the encoded 
proteins to raise antibodies. With these antibodies, we 
identified the CDC25 gene product as a 180 kDa 
polypeptide, which we named ~180’~~~, and showed 
that p 1 80cDcz5 is tightly attached to a membrane frac- 
tion of yeast cells. 
2. MATERIALS AND METHODS 
2.1. Preparation of hybrid proteins 
The plasmids of the pUR family are designed for IPTG-inducible 
expression of hybrid proteins encoded by in-frame fusion between the 
E. coli IacZ gene and any coding sequence [17]. A 1100 bp RsuI- 
EcoRl fragment, containing codons 86-493 of the CDC25 open 
reading frame, was inserted, using octameric synthetic BarnHI 
linkers, into pUR 292. The recombinant plasmid, named pPRl7, was 
introduced into TGl E. co/i cells [18] by the CaC12 transformation 
method [19]. A 1569 BglII-BglII fragment, containing codons 
354-877, was inserted into pUR 290. The recombinant plasmid, nam- 
ed pE2JM7, was introduced into JMlOl E. co/i cells [20]. Transform- 
ed cells culture, IPTG induction, and cell extraction were performed 
as described by Simon et al. [21]. Hybrid proteins were purified by 
affinity chromatography on APTG-Sepharose according to Ullmann 
[22]. They were used for rabbit immunization and antibody 
purification. 
2.2. Rabbit immunization and antibody purification 
Rabbit immunization was performed essentially as described by 
Part et al. [23]. 
For antibody purification, 8 mg pE2JM7 protein and 7 mg pPRl7 
protein were coupled each to 5 ml CNBr-activated Sepharose 4B 
(Pharmacia), according to manufacturer’s instructions. 
Immunoglobulin fraction was purified from crude serum by am- 
monium sulfate precipitation (45% saturation) and chromatography 
on a DEAE-Sephadex A-50 column equilibrated in 50 mM sodium 
acetate/21 mM acetic acid, pH 5 [24]. IgG were collected in the col- 
umn flow-through. The specific antibodies were purified by immuno- 
affinity chromatography on pEZJM7- or pPRl7-Sepharose columns, 
according to [25]. 
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2.3. Overexpression of the CDC25 gene 
pBM272 [26,27] contains the galactose-inducible GALl-GAL10 
yeast promoter inserted into the yeast/E. coli shuttle vector Ycp50 
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[28]. The CDC25 gene was inserted into pBM272 cut by BumHI and 
Nrul, as a 5362 bp XmnI-PvuII fragment. The blunt XmnI end was 
inserted into the BumHI site of pBM272 by use of synthetic octameric 
BarnHI linkers. The 5362 bp XmnI-PvuII fragment contains the en- 
tire CDC25 coding sequence, 126 bp upstream the first ATG codon 
and 466 bp downstream the STOP codon. The recombinant plasmid, 
named pGAL 25.6.1, was used to transform the thermosensitive 
c&25 mutant strain OL97.1.11 B (MATa, cdc25.5, ura3, Ieu2, His-) 
[12] and the protease-deficient yeast C13ABYS86 (pral-I, prbl-I, 
prcl-1, cpsl-3, uru3, leu2-3, His-) - a generous gift from D.H. 
Wolf - by the protoplast transformation method. 
2.4. CDC25 mRNA analysis 
Total and poly(A)+ mRNA extraction, electrophoresis, transfer 
and molecular hybridization were performed as described previously 
[9], except hat mRNA were transferred to Pall-Biodyne nylon mem- 
branes, according to manufacturer’s instructions. As a 
CDC25-specific DNA probe, we used a 767 bp KpnI-C/a1 fragment, 
inserted into the M13mp18 vector. As a control, we used a 615 bp 
EcoRI-Hind111 fragment of the TRPI gene [29] inserted into the 
M13mp19 vector. The single strand probes derived from MI3 
templates and labeled with [a-“P]dCTP (800 Ci/mmol) were obtain- 
ed by complementary DNA synthesis [30]. 
2.5. Whole cell protein extracts and subcellular fractionation 
Yeast cells were grown on minimal medium (yeast nitrogen base 
0.67%) supplemented with 0.5% casein acid hydrolysate and 
20 pg/ml uracil [31], containing either 2% glucose, or 3010 (w/v) 
glycerol plus 2% galactose. Yeast cells transformed either by pBM272 
or by pGAL25.6.1, were grown on the same media, but without 
uracil. Cells were harvested in log phase. For total protein extraction, 
frozen cells, resuspended in 0.2 M Tris-HCl, pH 8, 0.1 M NaCl and 
10% (v/v) glycerol, were broken by passage through a Nanton- 
Gaulin homogenizer. Proteases inhibitors were added just before ex- 
traction at the following final concentrations: 313 fig/ml benzamidin, 
1.36 pg/ml pepstatin-A, 0.26 pg/ml leupeptin, 2 pug/ml antipain, 
2 fig/ml chymostatin, 2 mM phenyl-methyl-sulfonyl-fluoride and 
4 mM o-phenanthrolin. 
For membrane preparations, yeast cells were broken by vigorous 
vortexing with glass beads (0.4 mm diameter) in ice-cold lysis buffer: 
50 mM Mes/KOH buffer, pH 6.2, 0.1 mM MgC12, 0.1 mM EGTA, 
1 mM 2-mercapto-ethanol and proteases inhibitors as above. The 
mixture was centrifuged at 800 x g for 5 min at +4”C to remove un- 
broken cells and glass beads. The crude cell extract was then cen- 
trifuged at 80000 x g for 1 h at +4”C. The supernatant was referred 
to as the cytosolic fraction, the pellet as the membrane fraction. 
Alternatively, yeast cells were broken by enzymatic digestion of cell 
walls with zymolyase (100 U/ml), in 0.1 M sodium acetate, 60 mM 
EDTA, 1.2 M sorbitol for 30-60 min at 30°C. Protoplasts were then 
washed with 10 ml of 50 mM Hepes/NaOH buffer, pH 7, 1 mM 
CaCl2, 10 mM MgC12, 0.1 mM EDTA, 1 mM MnCl2,0.8 M sorbitol 
(buffer B) and resuspended in 1 ml buffer B 1321. After addition of 
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3 ml of 50 mM Mes/KOH buffer, pH 6.2, 0.1 mM MgCI2, 0.1 mM 
EDTA and protease inhibitors (see above), protoplasts were 
homogenized by several strokes in a tightly fit Potter-Elvejheim ap- 
paratus. After elimination of unbroken cells and large debris by cen- 
trifugation at 200 x g for 10 min, crude membrane and cytosolic 
fractions were separated as above. Aliquots of this membrane frac- 
tion were incubated for 30 min at 0°C in the presence of 0.1 M 
Na2CO3,0.5 M potassium acetate, or 2.5 M urea [33]. Integral mem- 
brane proteins (pellet) and peripheral membrane proteins (superna- 
tant) were separated by centrifugation at 150000 x g for 1 h at +4OC. 
2.6. Electrophoresis and immunoblotting 
Whole cell extracts and various subcellular fractions were made 
1 x Laemmli sample buffer [34] with a 5 x solution and boiled 3 min 
prior to SDS-polyacrylamide gel electrophoresis. After elec- 
trophoresis and transfer to nitrocellulose sheets by the ‘semi-dry’ 
method [35], the membranes were processed as described by Part et 
al. [23]. Immunoreactive protein bands were detected by goat anti- 
rabbit IgG serum labelled with alkaline phosphatase (Promega 
Bio-Tech). 
3. RESULTS 
3.1. Very low transcription levels of the CDC25 gene 
allow suppression of cdc25 mutations 
Plasmid pGAL25.6.1 is a pBM272-based plasmid 
which contains the entire CDC25 open-reading-frame 
under control of a GALI promoter, and the URA3 
gene. 
We checked the ability of pGAL25.6.1 to comple- 
ment the thermosensitive cdc25 mutation of 
OL97.l.llB yeast cells (MA TO, cdc25-5, urajld, leu2, 
His-). Surprisingly, all the Ura+ transformants that we 
have tested could grow at restrictive temperature 
(36°C) whatever glucose or galactose is the carbon 
source. As expected, pBM272 transformed cells obtain- 
ed at 26°C were not able to grow at 36°C whatever 
glucose or galactose is the carbon source. Thus even 
when the GALZ promoter is repressed by the presence 
of glucose, the very low residual amount of transcrip- 
tion leads to suppression of the cdc2.5 mutation. 
To address this question of CDC25 expression on 
pGAL25.6.1 and overexpression in the presence of 
galactose, poly(A)+ mRNA were isolated from glucose 
- and galactose - grown cells (OL97.1.1lB yeasts 
transformed by pGAL25.6.1). After agarose gel elec- 
trophoresis and transfer to nylon membranes, these 
B 
Fig. 1. Northern blot analysis of transcription of the CDC25 gene cloned into the galactose-inducible expression vector pBM272. Poly(A)+ mRNA 
were prepared from 0L97.1 .llB cells transformed with pGAL25.6.1 and grown in the presence of either glucose (lanes l-4) or galactose (lanes 
5-8). After electrophoresis, RNA were transferred to a nylon membrane and probed with a CDC25 specific probe (part A) or a TRPI specific 
probe (part B). The following amounts were loaded on the gel: lanes 1 and 5, 10 fig; lanes 2 and 6,20 Fg; lanes 3 and 7,40 Pg; lanes 4 and 8, 80 pg. 
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MIWA were probed with a CDC25-specific, “P- 
labeled DNA probe. In glucose-grown c&s, CDC25 
mRNA was barely detectable. In gaiactase-grown cells, 
there was an about 50-fold induction of the CDC.25 
mRNA (Fig. 1). In both cases, the CLK?Z mRNA was 
of the expected size, around 5200 nucle~~ides ISIS This 
gaiactus~-induced accumuiat~on of CJ30S mRNA was 
not observed in yeasts transformed by pBM272. 
Did this enhancement of transcription promote an 
over-accumulation of the CDC25 gene product? In a 
preliminary experiment, whole ceil protein extracts 
from OLP7.1 .I 1B yeast cells trztnsformed by 
pGAL256.1 were analysed by immunoblottin~~ 
Polyclo,naf rabbit antibodies were raised against two 
hybrid proteins: pE2JM7 hybrid protein which COR- 
tains amino acids 345-877 of the CDC2.5 open reading 
frame and pPR 17 hybrid protein which contains amino 
acids 85-393 of the Ci?C25 open reading fraMe. Anti- 
pE2JM7 antibodies were named A2.4 and anti-pPRf7 
antibodies were named A&3, In galactase-grown ceils, 
an imm~~oreactive polyp~ptide was detected, having 
an apparent molecular mass of 31 kDa. This 31 kDa 
poiypeptide was not detected in glucose-grown ceils 
[data not shown). Therefore, to rule out proteolytic ar- 
tifacts, we used the strain C13ABYS86 which lacks four 
vacuolar proteases [36X. 
3.2. In a protease-deficimt yeasi strain, the prod& of 
the CDC25 gene is o 180 kDa ~~i~~~p~~de 
Whole protein extracts of yeast cells ~~13AB~~~~~ 
transformed by pGAL25.6.1, which contains the 
CDC2S gene under control of a gaiactose-inducibIe 
promoter, were analyzed by immunobl~~t~g. A2.4 an- 
tibodies detected a 180 kDa polypeptide (Fig. 2, lane 
d). This polypeptide, which we named plSOcDc*5, was 
detected only in cells grown on galactose, but not in 
cells grown on glucose (Fig. 2, lane c). It was detected 
neither in non-transformed ceils grown on glucose 
(Fig. 2, lane a) or galactose (Fig. 2, Iane b), nor in cells 
transformed with pBM272, the vector without insert 
(data tlot shawn), A&3 antibodies gave the same results 
(data not shown). 
3.3. p1&+=cZ5 is a~~~~~~~d with a ~~~~r~~e f~ac~iu~ 
The CL&Z25 gene product probably interacts with ras 
proteins, which in turn activate adenylate cyclase. Since 
ras proteins 1371 and adenylate cyclase f38J are located 
in the yeast plasmic membrane, we wondered wherfier 
p 18@=’ could be detected either in a soluble cytosolic 
fraction or in a rnernb~~~~ fraction. 
Yeast cells fC13ABYS86 strain tWnsformed by 
pGAL25.6.1 grown on @actose) were homogenized by 
vortexing with glass beads. The whole extract was frac- 
tionated by high-speed centrifugation between a 
cytosoIic fraction ~supe~~~tant) da membrane frac- 
tion (pellet). After elect~~phoresis and transfer, pro- 
teins were probed with A6.3 antibodies raised against 
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Fig. 2. ~rnrn~~~~t~ini~g of p180cW” in wfiok extraCtS of 
C13ABYS86 past cells. Whole E& extracts were run on 8% 
acrylamid5S~S gels. After transfer to nitr~e~~uios~, proteins were 
probed with A2.4 antibodies raised against pE2JM7 fusion protein 
which contains amino acids 354-877 of the cdc25 protein. (Lane a) 
No~-~r~~~~~~ yeasts grown on glucose minimal medium; {lane b) 
non-~ansfo~m~d yeasts grown on galactose minimal medium; [lane 
c) yeasts traorformed by pGAL25.6.1, grown on ghtcose minimaf 
medium; (ianne d) yeasts transformed by pGAL2kK6.1, grown on 
galactose rn~~~rn~ medium. 
the pPR17 hybrid protein, As shown in Fig. 3A, 
pl 80,cDc-zs was only detected in the membrane fraction 
(lane b). Similar results were obtained when cells were 
broken by ~ymolyase treatment followed by grinding of 
protoplasts in a Potter-Elvejheim apparatus (data not 
shown). 
We further checked whether plSr>cL”cIs was an in- 
tegral membrane protein or a peripheral membrane 
protein. After vortexing with glass beads, aliquots of 
the 80~0 X g Membrane pellet were incubated in the 
presence of 0.1 M Na#C&, pW 11, or 0.5 M potassium 
acetate, or 2.5 M urea 1331. Peripheral membrane pro- 
teins ~super~at~t~ were separated from integral mem- 
brane protein (pellet) by centrifugation at 150000 x g, 
After elect~~~horesis and transfer, the different frac- 
tions were probed with A&3 antibodies, As shown in 
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Fig. 3. Immunostaining of p180cDcz5 in membrane fractions of C13ABYS86 yeast cells transformed by pGAL25.6.1, grown on galactose minimal 
medium. After electrophoresis on polyacrylamide-SDS gels and transfer to nitrocellulose membranes, proteins were probed with A6.3 antibodies 
raised against pPR17 hybrid protein which contains amino acids 86-493 of the cdc25 protein. (A) Crude membrane separation (8% acrylamide 
gel). (Lane a) 80000 x g supernatant (cytosolic fraction); (lane b) 80000 x g pellet (crude membrane fraction). (B) Aliquots of crude membrane 
pellet were incubated in the presence of 0.1 M NazCOs, or 0.5 M potassium acetate, or 2.5 M urea. Peripheral membrane proteins (supernatant) 
were separated from integral membrane proteins (pellet) by a 150000 x g centrifugation. Equal amounts of each fraction were loaded on a 5% 
to 15% acrylamide gradient gel. (Lane a) Supernatant after urea treatment; (lane b) pellet after urea treatment; (lane c) supernatant after 
potassium acetate treatment; (lane d) pellet after potassium acetate treatment; (lane e) supernatant after NaKOs treatment; (lane f) pellet after 
Na2COs treatment. 
Fig. 3B, p180cDcz’ is predominantly detected in the in- 
tegral membrane fraction (lanes b, d and f). As observ- 
ed with whole cell extracts, p180cDcz5 was only detected 
in yeasts transformed by pGAL25.6.1 grown on 
galactose. 
In order to assess the quality of the membrane 
preparations, the same different fractions were probed 
with a ras antiserum (a generous gift from J.B. 
Crechet). As expected, ras proteins were only detected 
in the membrane fraction (Fig. 4A, lane b) and remain- 
ed predominantly associated with the integral mem- 
brane fraction after NazC03, potassium acetate, or 
urea treatment (Fig. 4B, lanes a, c and e). 
The results for ras proteins and ~180’~~ localiza- 
tion were identical, whatever method has been used for 
cell breakage. 
4. DISCUSSION 
The CDC25 gene contains an open reading frame of 
1589 codons, capable of encoding a 179 kDa protein 
[9,11,15]. By immunoblotting, we detected a polypep- 
56 














Fig. 4. Immunodetection of RAS proteins in membrane fractions of C13ABYS86 yeast cells transformed by pGAL25.6.1, grown on galactose 
minimal medium. The same fractions as in Fig. 3 were run on a 12% acrylamide-SDS gel, transferred to nitrocellulose sheets and probed with 
anti-ras antibodies. (A) Lane a, 80000 x g supernatant (cytosolic fraction); lane b, 80000 x g pellet (crude membrane fraction). (B) Lane a, pellet 
after NazCOs treatment; lane b, supernatant after NarCOs treatment; lane c, pellet after potassium acetate treatment; lane d, supernatant after 
potassium acetate treatment; lane e, pellet after urea treatment; lane f, supernatant after urea treatment. 
tide of apparent molecular mass 180 + 10 kDa which 
we named p180cDc25. This 180 kDa immunoreactive 
polypeptide is detected by two different sets of 
polyclonal antibodies raised against two different 
hybrid proteins encoded by two different parts of the 
CDC25 gene. pPR17 protein contains amino acids 
86-493 and pE2JM7 contains amino acids 354-877. So 
these two hybrid proteins represent only the N-terminal 
part of the CDC25 open reading frame. Even after 
purification on immunoaffinity columns, the two sets 
of antibodies, A2.4 and A6.3, still react with other pro- 
teins of lower apparent molecular mass than pl 80cDcz5. 
These cross-reacting species are not the same for each 
set of antibodies. Moreover, p180cDc25 is the only 
polypeptide whose detection requires both presence of 
pGAL25.6.1 and galactose induction. 
The pGAL25.6.1 recombinant plasmid contains the 
whole open reading frame of the CDC25 gene, 126 bp 
upstream the first ATG codon and 466 bp downstream 
the STOP codon. In this construct, the first ATG 
codon encountered ownstream the GAL2 promoter is 
the initiation codon of the CDC25 open reading frame 
[9]. In galactose-induced cells, the over-accumulated 
CDC25 mRNA was of the right size (5200 nucleotides), 
in good agreement with that previously reported for the 
mRNA transcribed from the CDC25 gene in its natural 
chromosomal location (5200 nucleotides) [9,16]. 
Therefore pl 80cDc25 represents the primary translation 
product of the CDC25 gene when cloned into the vector 
pGAL25.6.1. The apparent molecular weight on SDS- 
polyacrylamide gel is in good agreement with the 
molecular weight deduced from the open reading 
frame. That seems to exclude an important post- 
translational modification, such as glycosylation. 
57 
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However, since the antibodies have been raised against 
proteins expressed in E. coli, they could be unable to 
recognize yeast specific post-translational deter- 
minants. 
We were unable to detect p 1 80cDc25 in the absence of 
overexpression, which suggests p180cDc25 is not abun- 
dant in wild type cells. This low level is relevant to the 
very low amount of CDC25 mRNA detected and could 
explain that pGAL25 6.1 is able to complement CDC25 
deficient cells, even in the presence of glucose. 
Moreover, sequence analysis of the CDC25 open 
reading frame shows a strong bias in the codon usage 
index. p 1 80cDc2’ was only detected in the absence of 
proteolytic artefacts, by using the Cl3ABYS86 strain, 
which lacks four vacuolar proteases [36]. These 
vacuolar proteases have a broad specificity and are not 
likely to be involved in protein maturation. If pro- 
teolytic processing is essential for p180cDc25 function, 
none of the proteases defective in the C13ABYS86 
strain seems to be involved, since this strain is viable in 
the usual laboratory growth conditions, unlike CDC25 
deficient cells. However, our results cannot exclude a 
physiological proteolytic maturation of p180cDcz5 
We [ 12,141 and others [ IO,1 I] have proposed that the 
CDC25 gene product interacts with ras proteins to ac- 
tivate adenylate cyclase. In Saccharomyces cerevisiae, 
ras proteins and adenylate cyclase are bound to the 
membrane. We found p180cDczs associated with the 
membrane fraction after cell breakage by two different 
methods. No significant amount was found in the 
cytosolic fraction. To check the attachment of 
p 1 8ocDc25 to the membrane, we performed stripping 
experiments of the crude membrane fraction by three 
different reagents able to release only peripheral mem- 
brane proteins. These three methods gave essentially 
the same results: when we loaded equal protein 
amounts, p180cDc25 immunostaining was found almost 
exclusively in the integral membrane protein fraction. 
However, if we take into account the total amount of 
p 1 80CDc2’ present in each fraction, a low but signifi- 
cant amount of ~180 cDc25 has been released from the 
membranes by such treatments. The same repartition 
was observed for ras proteins. 
Roadway et al. [39] pointed out the presence of a 
SH3 sequence between amino acids 65 and 129 of the 
CDC25 gene product. This SH3 sequence is present in 
the N-terminal parts of several proteins bound to a 
submembranous actin cytoskeleton, such as c-src [40], 
v-crk [41], fodrin [42] and myosin IB [43]. Fodrin [44] 
and myosin IB [43] are released from membrane 
preparations by 1 M KC1 or 100 mM NaOH, which 
release peripheral membrane proteins [45]. By contrast, 
p 1 80cDcz5 is only partially released from membranes by 
treatments known to release peripheral membrane pro- 
teins. This suggests ome other way than the presence 
of a SH3 sequence for anchoring p180cDc25 into the 
membrane. We have shown that p180cDc25 is bound to 
58 
the membrane as tightly as ras proteins, which are an- 
chored into the membrane via post-translational acyla- 
tion [37]. How p180cDc2’ is anchored into the 
membrane remains to be elucidated. It could be by 
means of a putative transmembrane domain as already 
proposed by others [46,47]. Anyway, it could be func- 
tionally relevant hat p180cDc25 and ras proteins, which 
together activate adenylate cyclase, are both bound to 
the membrane. 
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